AKTS

Aktis OncologyB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$40.00

Analysis reference price unavailable

Analysis 2026-07-29 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$27.00

Analysis reference price unavailable

Analysis 2026-07-29 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$15.00

Analysis reference price unavailable

Analysis 2026-07-29 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-29

AI commentary

News tone is mixed-to-cautious: clinical progress and planned 2027 data provide forward hooks, while AP/Zacks coverage highlighted an EPS miss and recent insider filings showed open-market sales. Social sentiment, options skew, short interest, employee ratings, and post-print analyst revisions are unavailable; low coverage limits confidence.

RankAlpha Sentiment Codex - 2026-07-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-31catalystPost-earnings miss and insider-sale overhangMedium impact

Q1 results were reported as an EPS miss versus the cited Zacks consensus despite revenue above expectations; COO and CMO Form 4 filings also show open-market sales on July 8. These factors may keep near-term sentiment cautious. [#PR-EARNINGS-2026-05-12] [#SEC-FORM4-2026-07-10]

2026-12-31eventAKY-2519 basket-trial expansionHigh impact

Aktis initiated the AKY-2519 Phase 1b mCRPC trial and plans a second Phase 1b basket trial in additional solid tumors during the second half of 2026. Execution would provide an intermediate development milestone. [#SEC-8K-2026-05-11]

2027-03-31catalystPreliminary clinical data from AKY-2519 and AKY-1189High impact

Management expects preliminary AKY-2519 data in 2027 and preliminary AKY-1189 Phase 1b data in the first quarter of 2027. These are the main potential value inflection points, but efficacy and safety remain unproven. [#SEC-8K-2026-05-11]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-29 • Updated nightlySource: Internal modelMethodology